Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) Stock Has Average Target Price of $10.00 According to Analysts

Posted by George Bondi on Nov 1st, 2026

Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE – Get Free Report) has been given an average recommendation of “Moderate Buy” by the seven research firms that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and five have issued a buy recommendation on the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $10.00.

Several brokerages recently commented on ATHE. Craig Hallum set a $2.00 target price on Alterity Therapeutics in a report on Tuesday, August 11th. Lake Street Capital started coverage on shares of Alterity Therapeutics in a report on Tuesday, September 15th. They issued a “buy” rating and a $10.00 price target on the stock. UBS Group set a $12.00 price objective on Alterity Therapeutics in a research note on Tuesday, August 11th. Finally, Weiss Ratings raised shares of Alterity Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, October 12th.

Read Our Latest Stock Analysis on ATHE

Alterity Therapeutics Trading Down 3.1%

Shares of ATHE opened at $2.16 on Friday. The company’s fifty day moving average is $3.50 and its two-hundred day moving average is $3.97. Alterity Therapeutics has a fifty-two week low of $2.01 and a fifty-two week high of $5.89.

Alterity Therapeutics (NASDAQ:ATHE – Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The company reported ($0.28) EPS for the quarter. The firm had revenue of $0.31 million during the quarter. As a group, equities analysts forecast that Alterity Therapeutics will post -0.12 EPS for the current fiscal year.

Institutional Trading of Alterity Therapeutics

A hedge fund recently raised its position in Alterity Therapeutics stock. Greenleaf Trust grew its position in Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE – Free Report) by 93.8% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 62,000 shares of the company’s stock after purchasing an additional 30,000 shares during the period. Greenleaf Trust owned approximately 0.70% of Alterity Therapeutics worth $333,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 2.14% of the company’s stock.

Alterity Therapeutics Company Profile

(Get Free Report)

Alterity Therapeutics Limited (NASDAQ: ATHE) is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases. The company’s research centers on abnormal protein accumulation and misfolding, biological processes associated with conditions such as Parkinson’s disease and Alzheimer’s disease.

Alterity’s lead investigational therapy is buntanetap, formerly known as PBT434. The small-molecule drug is designed to inhibit the formation of toxic misfolded proteins, including alpha-synuclein and tau, with the goal of slowing or preventing disease progression.